Jan 30, 2025 · BioPharma Dive provides news and analysis for biotech and biopharmaceutical executives. We cover topics like clinical trials, drug discovery and development, pharma marketing, FDA approvals and regulations, and more.

4 days ago · The biopharma industry outlook on 2025: Uncertainty and change The Trump administration is bringing new instability to a sector already grappling with a shaky market as well as threats like competition from China.

Jan 2, 2025 · A company spokesperson told BioPharma Dive results should be available sometime in 2025. Analysts from the investment bank Jefferies have estimated the findings could disclosed as early as the first half, although a federal database lists …

Jan 14, 2025 · Since hitting a record high in 2021, the number of biotech IPOs per year has settled around 20. Last year’s 23 stock issuances were primarily priced by biotechs with drugs in mid-to-late stage testing, according to BioPharma Dive data. Meanwhile, the startups that formed during the pandemic-era funding boom have matured.

Jan 28, 2025 · Finally, BioPharma Dive updates the tracker when deals are announced. Sometimes, transactions fall through or another company outbids the original acquirer. In the former case, we remove the deal from our database; …

5 days ago · By BioPharma Dive staff • Feb. 7, 2025 Permission granted by Bristol-Myers Squibb Bristol Myers, bracing for key patent losses, deepens cost-cutting plan

Jan 16, 2024 · Brian Tucker / BioPharma Dive Guarded optimism seems to be the mood of the biopharmaceutical industry to start 2024. Last year brought a stock market slide and layoffs for more than 150 drug companies.

Jan 16, 2025 · BIOPHARMA DIVE: You were Roche’s head of business group development for 12 years, a period which brought the rise of immuno-oncology, the ups and downs of cell and gene therapy, and, more recently, a bit of a resurgence in neuroscience and a …

Jan 21, 2025 · Will 2025 herald a sudden turnaround for biopharma? Unlikely, but continued recovery is likely with some strong growth in therapy areas including cancer, diabetes and – inevitably – obesity. Four of the top 10 drugs by prescription sales in 2025 will be from the new incretin class, according to the latest analysis by Evaluate. Consensus ...

Dec 10, 2024 · An experimental drug from NewAmsterdam Pharma has shown it may protect heart health in a Phase 3 study, a finding Wall Street analysts believe boosts the medicine’s chances of improving the outcomes of people with cardiovascular disease in an ongoing, closely watched clinical trial.